LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Search

Co-Diagnostics Inc

Atvērts

SektorsVeselības aprūpe

0.35

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

0.34

Max

0.35

Galvenie mērījumi

By Trading Economics

Ienākumi

1.8M

-5.9M

Pārdošana

-18K

145K

Peļņas marža

-4,049.266

Darbinieki

132

EBITDA

1M

-6.7M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+316.67% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-2.4M

21M

Iepriekšējā atvēršanas cena

0.35

Iepriekšējā slēgšanas cena

0.35

Ziņu noskaņojums

By Acuity

50%

50%

195 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

Co-Diagnostics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 10. dec. 22:02 UTC

Peļņas

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

2025. g. 10. dec. 21:46 UTC

Peļņas

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

2025. g. 10. dec. 23:52 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

2025. g. 10. dec. 23:43 UTC

Tirgus saruna

Nikkei May Rise After Fed Rate Cut -- Market Talk

2025. g. 10. dec. 23:36 UTC

Tirgus saruna

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

2025. g. 10. dec. 23:20 UTC

Peļņas

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

2025. g. 10. dec. 23:15 UTC

Peļņas

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

2025. g. 10. dec. 22:59 UTC

Tirgus saruna
Peļņas
Iegādes, apvienošanās, pārņemšana

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

2025. g. 10. dec. 22:45 UTC

Tirgus saruna

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

2025. g. 10. dec. 22:40 UTC

Peļņas

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

2025. g. 10. dec. 22:06 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

2025. g. 10. dec. 22:06 UTC

Peļņas

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

2025. g. 10. dec. 22:02 UTC

Peļņas

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

2025. g. 10. dec. 22:00 UTC

Peļņas

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

2025. g. 10. dec. 21:53 UTC

Peļņas

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

2025. g. 10. dec. 21:50 UTC

Iegādes, apvienošanās, pārņemšana

Investors Bet That a Higher Bid for Warner Is Coming -- Update

2025. g. 10. dec. 21:50 UTC

Tirgus saruna
Peļņas
Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2025. g. 10. dec. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 10. dec. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 10. dec. 21:45 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

2025. g. 10. dec. 21:33 UTC

Peļņas

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

2025. g. 10. dec. 21:32 UTC

Peļņas

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

2025. g. 10. dec. 21:28 UTC

Iegādes, apvienošanās, pārņemšana

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

2025. g. 10. dec. 21:25 UTC

Peļņas

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

2025. g. 10. dec. 21:18 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

2025. g. 10. dec. 21:16 UTC

Peļņas

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

2025. g. 10. dec. 21:15 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

2025. g. 10. dec. 21:15 UTC

Peļņas

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

2025. g. 10. dec. 21:14 UTC

Peļņas

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

2025. g. 10. dec. 21:14 UTC

Peļņas

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Salīdzinājums

Cenas izmaiņa

Co-Diagnostics Inc Prognoze

Cenas mērķis

By TipRanks

316.67% augšup

Prognoze 12 mēnešiem

Vidējais 1.5 USD  316.67%

Augstākais 1.5 USD

Zemākais 1.5 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Co-Diagnostics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

1

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

0.3495 / 0.3699Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

No Evidence

Noskaņojums

By Acuity

195 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Co-Diagnostics Inc

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat